Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing

Autor: Eleonora P M Corssmit, Thomas M.A. Kerkhofs, Henri J L M Timmers, Marelise Eekhoff, Liselotte van Deun, Henk-Jan Guchelaar, Michiel N. Kerstens, Hans Gelderblom, Anyue Yin, Jesse J. Swen, Antonio D'Avolio, Madeleine H.T. Ettaieb, Dirk Jan A.R. Moes, Robert J.H.M. van der Straaten, Richard A Feelders, Jessica Cusato, Harm R. Haak

Publikováno v: Clinical Pharmacokinetics
Clinical Pharmacokinetics, 60, 89-102
Yin, A, Ettaieb, M H T, Swen, J J, van Deun, L, Kerkhofs, T M A, van der Straaten, R J H M, Corssmit, E P M, Gelderblom, H, Kerstens, M N, Feelders, R A, Eekhoff, M, Timmers, H J L M, D’Avolio, A, Cusato, J, Guchelaar, H J, Haak, H R & Moes, D J A R 2021, ' Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma : Towards Individualized Dosing ', Clinical Pharmacokinetics, vol. 60, no. 1, pp. 89-102 . https://doi.org/10.1007/s40262-020-00913-y
Clinical Pharmacokinetics, 60(1), 89-102. Adis International Ltd
Clinical Pharmacokinetics, 89-102. Springer International Publishing AG
ISSUE=1;STARTPAGE=89;ENDPAGE=102;ISSN=0312-5963;TITLE=Clinical Pharmacokinetics
Clinical Pharmacokinetics, 60(1), 89-102. Adis
Clinical Pharmacokinetics, 60, 1, pp. 89-102
Clinical Pharmacokinetics, 60, 89-102. ADIS INT LTD

Background Mitotane is the only approved treatment for patients with adrenocortical carcinoma (ACC). A better explanation for the variability in the pharmacokinetics (PK) of mitotane, and the optimization and individualization of mitotane treatment,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93a96040ee3ce7635be4ded6e6cc14c5
http://hdl.handle.net/2318/1788848